Nucleic Acid Therapeutics Market Set for Strong Growth to US$ 14.42 Billion by 2032, Led by North America's 42.5% Market Share

The Global Nucleic Acid Therapeutics Market reached US$ 5.64 billion in 2024 and is expected to reach US$ 14.42 billion by 2032, growing at a CAGR of 10.9% during the forecast period 2025-2032.

The market is rapidly expanding as biotech firms and pharma giants advance mRNA vaccines, gene silencing therapies, and CRISPR-based editing tools, fueled by rising demand for personalized medicine and accelerated regulatory approvals post-COVID. This growth reflects a fundamental shift in healthcare treatment paradigms, moving away from small-molecule drugs toward precision nucleic acid platforms that target genetic root causes of diseases like cancer, rare disorders, and infectious outbreaks with unprecedented specificity.

Request Executive Sample Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/nucleic-acid-therapeutics-market?ram

Key Industry Developments

United States:
✅ February 2026: Moderna announced advancements in mRNA-based nucleic acid therapeutics for rare genetic disorders, launching Phase 3 clinical trials with improved lipid nanoparticle delivery systems for enhanced targeting and reduced off-target effects.

✅ December 2025: Ionis Pharmaceuticals unveiled R&D progress on antisense oligonucleotides (ASOs) for neurodegenerative diseases, securing FDA fast-track designation for a lead candidate targeting spinal muscular atrophy with novel backbone chemistry.

✅ October 2025: Alnylam Pharmaceuticals launched a next-generation siRNA therapeutic for ATTR amyloidosis, featuring enhanced GalNAc conjugation for liver-specific delivery and prolonged half-life.

Japan:
✅ January 2026: Takeda Pharmaceutical released updates on their nucleic acid therapeutics platform, advancing aptamer-based drugs into clinical development for hemophilia with improved binding affinity and oral bioavailability.

✅ November 2025: Astellas Pharma reported technological breakthroughs in miRNA therapeutics for cancer, initiating first-in-human trials with proprietary nanoparticle encapsulation to overcome extracellular barriers.

✅ October 2025: Chugai Pharmaceutical (Roche affiliate) announced a product launch extension of anti-sense nucleic acid drugs for metabolic disorders, incorporating stereopure oligonucleotides for higher potency and reduced dosing frequency.

Strategic Acquisitions and Partnerships
✅ Novartis AG acquired Regulus Therapeutics Inc. in June 2025, enhancing its RNA-targeted drug development pipeline for rare and chronic diseases in the nucleic acid therapeutics space.
​
✅ Leading players like Pfizer Inc., Sanofi S.A., Novartis AG, Moderna Inc., and BioNTech SE expanded their antisense oligonucleotide and RNA platforms through strategic investments and partnerships throughout 2025.​

Key Players:
Ionis Pharmaceuticals | Alnylam Pharmaceuticals, Inc. | Gilead Sciences, Inc. | AstraZeneca | Sarepta Therapeutics, Inc. | Creative Biolabs | GSK plc | Novartis AG | BioNTech SE | Silence Therapeutics

Strategic Leadership Analysis: Top 5 Players in Nucleic Acid Therapeutics Market 2026
-Ionis Pharmaceuticals: Advanced RNA-targeted therapeutics with the launch of olezarsen, achieving 75% triglyceride reduction in Phase 3 for familial chylomicronemia syndrome, and expanded neurology pipeline using proprietary MsPA backbone technology for rare diseases like prion disease and genetic dementia.

-Alnylam Pharmaceuticals, Inc.: Pioneered siRNA-based treatments with the recent approval and rollout of vutrisiran (Amvuttra) for ATTR amyloidosis, offering quarterly subcutaneous dosing with superior efficacy over prior therapies, alongside Amgallig for primary hyperoxaluria type 1 entering late-stage development.

-Sarepta Therapeutics, Inc.: Delivered Elevidys as the first gene therapy-like RNA modality for Duchenne muscular dystrophy via micro-dystrophin delivery, with expanded FDA approval to broader patient populations and ongoing advancements in next-generation antisense oligonucleotides for rare neuromuscular disorders.

-BioNTech SE: Expanded nucleic acid platform beyond mRNA vaccines with fijinlermin, a next-generation lipoplex-formulated mRNA therapeutic entering Phase 2 for advanced solid tumors, and BNT116, an mRNA vaccine combined with checkpoint inhibitors showing promising early data in lung cancer trials.

-Silence Therapeutics: Progressed mRNAi GOLD platform with SLN360 demonstrating Phase 2 proof-of-concept in reducing Lp(a) levels by over 80% for cardiovascular risk reduction, alongside SLN124 advancing in polycythemia vera with durable erythropoietin suppression and favorable safety profile.

Purchase Corporate License | Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=nucleic-acid-therapeutics-market?ram

Main Drivers and Trends Shaping the Future of Nucleic Acid Therapeutics Market
-Advancements in Gene Editing: CRISPR-Cas9 and similar technologies enable precise DNA modifications, revolutionizing treatments for genetic disorders like cystic fibrosis and muscular dystrophy.

-Rising Genetic Disease Burden: Increasing prevalence of chronic conditions such as neuromuscular diseases, cancer, and hATTR drives demand for targeted therapies like ASOs and siRNAs.

-Delivery Innovation: Lipid nanoparticles (LNPs) dominate with proven efficacy in mRNA vaccines, enhancing safety and specificity for broader nucleic acid drug applications.​

-AI Integration: Biotechnology leverages AI for drug discovery and optimization, accelerating development pipelines for personalized medicine.​

-Market Hurdles: High therapy development costs, complex manufacturing, and stringent regulatory approvals pose key constraints to scalable growth.

Regional Insights:
-North America: 42.5% (Largest share, driven by established biotech hubs, high R&D spending, and rapid adoption of therapies like ASOs and siRNAs).​

-Asia Pacific: 25% (Fastest growing, fueled by expanding healthcare in China, India, and Japan, plus rising genetic disease prevalence).

-Europe: 20% (Supported by regulatory approvals, EMA backing for RNA therapies, and steady biopharma investments).​​

Market Opportunities & Challenges: Nucleic Acid Therapeutics Market 2026
-Opportunities: A "Delivery Innovation Surge" accelerates platform licensing; lipid nanoparticle (LNP) enhancements and exosome vectors enable tissue-specific targeting for neurodegeneration and cardiovascular indications. Expanded mRNA pipelines for infectious diseases plus AI-optimized siRNA designs attract cross-pharma partnerships for common chronic conditions.

-Challenges: "Manufacturing Scale Hurdles" persist from complex synthesis purity demands, while off-target immunogenicity risks demand advanced safety profiling. Success hinges on mastering fragmented global GMP supply chains and harmonizing divergent FDA/EMA approval pathways.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/nucleic-acid-therapeutics-market?ram

Market Segmentation Analysis:
-By Category: Antisense Oligonucleotides Dominate with Proven Efficacy
Antisense Oligonucleotides (ASOs) lead at 45% market share in 2025, targeting faulty RNA to treat genetic disorders and cancers via precise gene silencing.
Small Interfering RNA (siRNA) holds 25%, using RNA interference for viral infections and rare diseases with high specificity.​
Messenger RNA (mRNA) captures 20%, powering vaccines and protein replacement therapies post-COVID advancements.​
Self-Amplifying RNA (saRNA) takes 10%, amplifying expression for potent, low-dose vaccines in infectious diseases.​

-By Application: Cancers Lead Amid High Demand
Cancers command 40% share, leveraging nucleic acids for targeted oncology therapies like tumor suppression.
Viral Infections follow at 25%, boosted by mRNA/siRNA vaccines for pandemics and antivirals.​
Genetic Disorders hold 20%, addressing rare mutations with ASOs and gene modulation.​
Others account for 15%, covering autoimmune and neurological uses.​

-By End-User: Hospitals Drive Clinical Adoption
Hospitals lead with 55% share, providing acute delivery for cancer and infection treatments.
Academic & Research Institutes take 30%, fueling trials and early development.​
Others (clinics, pharma) split 15%, supporting outpatient and specialized care.​

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?ram

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTW

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.